Flecainide

Template:Short description Template:Use dmy dates Template:Cs1 config Template:Drugbox Flecainide is a medication used to prevent and treat abnormally fast heart rates.<ref name=AHFS2019/> This includes ventricular and supraventricular tachycardias.<ref name=AHFS2019/> Its use is only recommended in those with dangerous arrhythmias or when significant symptoms cannot be managed with other treatments.<ref name=AHFS2019/> Its use does not decrease a person's risk of death.<ref name=AHFS2019/> It is taken by mouth or injection into a vein.<ref name=AHFS2019/><ref name=BNF76/>

Common side effects include dizziness, problems seeing, shortness of breath, chest pain, and tiredness.<ref name=AHFS2019/> Serious side effects may include cardiac arrest, arrhythmias, and heart failure.<ref name=AHFS2019/> It may be used in pregnancy, but has not been well studied in this population.<ref name=BNF76/><ref>Template:Cite web</ref> Use is not recommended in those with structural heart disease or ischemic heart disease.<ref name=AHFS2019/> Flecainide is a class Ic antiarrhythmic agent.<ref name=AHFS2019/> It works by decreasing the entry of sodium in heart cells, causing prolongation of the cardiac action potential.<ref name=AHFS2019/>

Flecainide was approved for medical use in the United States in 1985.<ref name=AHFS2019>Template:Cite web</ref> It is available as a generic medication.<ref name=BNF76>Template:Cite book</ref> In 2023, it was the 223rd most commonly prescribed medication in the United States, with more than 1Template:Nbspmillion prescriptions.<ref>Template:Cite web</ref><ref>Template:Cite web</ref> Template:TOC limit

Medical uses

Flecainide is used in the treatment of many types of supraventricular tachycardias, including AV nodal reentrant tachycardia (AVNRT) and Wolff-Parkinson-White syndrome (WPW).

It also has limited use in the treatment of certain forms of ventricular tachycardia (VT). In particular, flecainide has been useful in the treatment of ventricular tachycardias that are not in the setting of an acute ischemic event. It has use in the treatment of right ventricular outflow tract (RVOT) tachycardia<ref name = Gill>Template:Cite journal</ref> and in the suppression of arrhythmias in arrhythmogenic right ventricular dysplasia (ARVD).<ref name = Sakurada>Template:Cite journal</ref> Studies (notably the Cardiac Arrhythmia Suppression Trial) have shown an increased mortality when flecainide is used to suppress ventricular extrasystoles in the setting of acute myocardial infarction.<ref name = Echt>Template:Cite journal</ref><ref name = Greenberg>Template:Cite journal</ref>

Flecainide can be used for the management of atrial fibrillation.<ref name=":0" />

In individuals suspected of having the Brugada syndrome, the administration of flecainide may help reveal the electrocardiography (ECG) findings that are characteristic of the disease process. This may help make the diagnosis of the disease in equivocal cases.<ref name = Gasparini>Template:Cite journal</ref>

In the long-term, flecainide seems to be safe in people with a healthy heart with no signs of left ventricular hypertrophy, ischemic heart disease, or heart failure.<ref name=":0">Template:Cite journal</ref>

Side effects

Results of a medical study known as the Cardiac Arrhythmia Suppression Trial (CAST) demonstrated that patients with structural heart disease (such as a history of MI (heart attack), or left ventricular dysfunction) and also patients with ventricular arrhythmias, should not take this drug. The results were so significant that the trial was stopped early and preliminary results were published.<ref name = CAST>Template:Cite journal</ref>

The dose may need to be adjusted in certain clinical scenarios. As with all other antiarrhythmic agents, there is a risk of proarrhythmia associated with the use of flecainide. This risk is probably increased when flecainide is co-administered with other class Ic antiarrhythmics, such as encainide. The risk of proarrhythmia may also be increased by hypokalemia.<ref name = Ohki>Template:Cite journal</ref> The risk of proarrhythmia is not necessarily associated with the length of time an individual is taking flecainide, and cases of late proarrhythmia have been reported.<ref name = Morganroth>Template:Cite journal</ref>

Because of the negative inotropic effects of flecainide, it should be used with caution in individuals with depressed ejection fraction, and may worsen congestive heart failure in these individuals. It should be avoided in people with ischaemic heart disease and the elderly.<ref name = Santinelli/>

As with all class I antiarrhythmic agents, flecainide increases the capture thresholds of pacemakers.<ref name = Fornieles-Pérez>Template:Cite journal</ref><ref>Template:Cite journal</ref>

Treatment

Treatment of flecainide cardiac toxicity involves increasing the excretion of flecainide, blocking its effects in the heart, and (rarely) institution of cardiovascular support to avoid impending lethal arrhythmias. Modalities that have had success include administration of a beta-sympathomimetic agent,<ref name = Winkelmann>Template:Cite journal</ref> and administration of a sodium load<ref name = Winkelmann/>(often in the form of hypertonic sodium bicarbonate). Placing the individual on cardiopulmonary bypass support may be necessary in order to temporarily remove the need for a beating heart and to increase blood flow to the liver.<ref name = Corkeron>Template:Cite journal</ref><ref name = Yasui>Template:Cite journal</ref>

Lungs

Flecainide has a very high affinity for lung tissue <ref>Template:Cite journal</ref> and is associated with drug-induced interstitial lung disease.<ref>Template:Cite journal</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref><ref>Template:Cite journal</ref>

Interactions

Flecainide has high bioavailability after an oral dose,<ref name = Smith>Template:Cite journal</ref> meaning that most of the drug that is ingested will enter the systemic blood stream. Peak serum concentrations can be seen 1 to 6 hours after ingestion of an oral dose. While the plasma half-life is about 20 hours, it is quite variable, and can range from 12 to 27 hours.<ref name = Padrini>Template:Cite journal</ref> During oral loading with flecainide, a steady state equilibrium is typically achieved in 3 to 5 days.

The majority of flecainide is eliminated by the kidneys, with the remainder metabolized by the cytochrome P450 2D6 isoenzyme in the liver.<ref name = Haefeli>Template:Cite journal</ref> Therefore, alterations in renal function or urine pH will greatly affect the elimination of flecainide, as more is eliminated by the kidney than by the hepatic route.

Because of the dual elimination routes of flecainide and its tendency to decrease myocardial contractility,<ref name = Santinelli>Template:Cite journal</ref> flecainide interacts with numerous pharmaceuticals and can potentiate the effects of other myocardial depressants and AV node blocking agents.

Overdose

Flecainide intoxication is rare but serious due to the cardiogenic shock that it provokes. Its diagnosis can be difficult in the lack of contributing anamnestic elements. Clinical and paraclinical signs are not specific. Treatment is primarily symptomatic, which gives good results thanks to the hypertonic solution of sodium salts. Organ donation is possible in the case of braindead patients who had a flecainide intoxication.<ref>Template:Cite journal</ref>

Mechanism of action

Flecainide works by blocking the Nav1.5 sodium channel in the heart, slowing the upstroke of the cardiac action potential.<ref name = Ramos>Template:Cite journal</ref>

The effect of flecainide on the sodium channels of the heart increases as the heart rate increases; This is known as use-dependence and is why that flecainide is useful to break a tachyarrhythmia.<ref name = Wang>Template:Cite journal</ref>

Flecainide also inhibits ryanodine receptor 2 (RyR2),<ref name="pmid25274603">Template:Cite journal</ref> a major regulator of sarcoplasmic release of stored calcium ions. It can reduce calcium sparks and thus arrhythmogenic calcium waves in the heart.<ref name="pmid19835880">Template:Cite journal</ref> While Flecainide therapy has been shown to suppress ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) and mouse models of this disease, the relative contribution from the inhibition of sodium channels and of RyR2 in this effect on CPVT is unclear.<ref name="pmid25858058">Template:Cite journal</ref>

Society and culture

Brand names

Flecainide is sold under the brand name Tambocor (manufactured by 3M pharmaceuticals). Flecainide went off-patent in February 2004. In addition to being marketed as Tambocor, it is available in generic version and under the brand names Almarytm, Apocard, Ecrinal, and Flécaine.